Stock Monitor: Amgen Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 26, 2018 / Active-Investors.com has just released a free research report on argenx SE (NASDAQ: ARGX). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ARGX as the Company's latest news hit the wire. On April 24, 2018, the Company announced that it will present complete data from the Phase-2 proof-of-concept trial assessing efgartigimod (ARGX-113) in generalized myasthenia gravis (MG) patients at the 2018 American Academy of Neurology (AAN) Annual Meeting in Los Angeles, California. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Amgen Inc. (NASDAQ: AMGN), which also belongs to the Healthcare sector as the Company argenx. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=AMGN

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, argenx most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ARGX

Argenx will Report Data from Two Additional Indications, Immune Thrombocytopenia, and Pemphigus Vulgaris in 2018

Nicolas Leupin, Chief Medical Officer of argenx, stated that the data show an early separation between treatment and placebo groups on efficacy scores that persisted for the total duration of the study. According to him, this may be as a differentiator from current therapies for managing IgG levels, including plasmapheresis, where benefit reversed more rapidly.

Nicolas further said that the Company continues to learn more about the novel mechanism of action of its drug candidate and look forward to reporting data from two additional indications this year, immune thrombocytopenia, and pemphigus vulgaris, which like MG, are diseases mediated by pathogenic IgGs.

Phase-2 Proof-of-Concept Trial

The Phase-2 trial evaluated 24 MG patients, who were randomized to receive four weekly doses of either standard of care plus 10 mg/kg of ARGX-113, or standard of care plus placebo. Standard of care therapies included acetylcholinesterase inhibitors, corticosteroids, and immunomodulatory agents. The primary endpoints of the trial were safety and tolerability. Secondary endpoints included efficacy as measured by the change from baseline of the Myasthenia Gravis Activity-of-Daily-Living (MG-ADL), Quantitative Myasthenia Gravis (QMG) and Myasthenia Gravis Composite (MGC) disease severity scores; impact on quality of life as measured by the Myasthenia Gravis Quality of Life (MGQoL) score; and an assessment of pharmacokinetics (PK); and pharmacodynamic (PD) markers and immunogenicity.

Efgartigimod Treatment Resulted in Clinical Improvement over Placebo as Measured by MG-ADL, QMG, MGC and MG-QoL

Data show that administration of efgartigimod resulted in clinical improvement over the placebo through the entire duration of study. Clinical benefit in the efgartigimod treatment group maximized as of one week after the administration of the last dose, achieving statistical significance over the placebo group on MG-AD) score. 75% of patients treated with efgartigimod had a clinically meaningful and statistically significant improvement in MG-ADL scores for a period of at least six consecutive weeks versus 25% of patients on the placebo. Efgartigimod treatment resulted in clinical improvement over the placebo, as measured by all four predefined clinical efficacy scales - MG-ADL, QMG, MGC, and MG-QoL.

All patients in the treatment arm showed a reduction of total IgG levels. Clinically meaningful disease improvement was found to correlate with reduction in pathogenic IgG levels. The tolerability of efgartigimod remained consistent with findings from the Phase-1 trial in healthy volunteers.

About Myasthenia Gravis

Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. The most commonly affected muscles are those of the eyes, face, and swallowing. It can result in double vision, drooping eyelids, trouble talking, and trouble walking. Onset can be sudden. Those affected often have a large thymus gland or develop a thymoma. MG is an autoimmune disease which results from antibodies that block or destroy nicotinic acetylcholine receptors at the junction between the nerve and muscle. This prevents nerve impulses from triggering muscle contractions.

About Efgartigimod

Efgartigimod (ARGX-113) is an investigational therapy for IgG-mediated autoimmune diseases and was designed to exploit the natural interaction between IgG antibodies and the recycling receptor FcRn. ARGX-113 is the Fc-portion of an antibody that has been modified by the argenx proprietary ABDEG(TM) technology to increase its affinity for FcRn beyond that of normal IgG antibodies. As a result, ARGX-113 blocks antibody recycling through FcRn binding and leads to fast depletion of the autoimmune disease-causing IgG autoantibodies.

About Argenx SE

Founded in 2008 and based in Breda, the Netherlands, argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer.

Stock Performance Snapshot

April 25, 2018 - At Wednesday's closing bell, argenx's stock slightly fell 0.46%, ending the trading session at $86.30.

Volume traded for the day: 60.56 thousand shares.

Stock performance in the last month ? up 8.66%; previous three-month period ? up 13.67%; past six-month period ? up 270.78%; and year-to-date - up 36.68%

After yesterday's close, argenx's market cap was at $2.32 billion.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors